Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GLAXF) Long-Term Debt Issuances (2017 - 2025)

Historic Long-Term Debt Issuances for Gsk (GLAXF) over the last 14 years, with Q3 2025 value amounting to -$5.4 million.

  • Gsk's Long-Term Debt Issuances changed N/A to -$5.4 million in Q3 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year increase of 10954.71%. This contributed to the annual value of $2.6 billion for FY2025, which is 8991.94% up from last year.
  • Latest data reveals that Gsk reported Long-Term Debt Issuances of -$5.4 million as of Q3 2025.
  • In the past 5 years, Gsk's Long-Term Debt Issuances registered a high of $12.4 billion during Q1 2022, and its lowest value of -$23.2 billion during Q2 2022.
  • Moreover, its 4-year median value for Long-Term Debt Issuances was -$161.7 million (2023), whereas its average is -$1.4 billion.
  • Its Long-Term Debt Issuances has fluctuated over the past 5 years, first surged by 7697.85% in 2023, then tumbled by 39851.15% in 2024.
  • Gsk's Long-Term Debt Issuances (Quarter) stood at -$1.2 billion in 2022, then surged by 76.98% to -$276.8 million in 2023, then tumbled by 398.51% to -$1.4 billion in 2024, then soared by 99.61% to -$5.4 million in 2025.
  • Its Long-Term Debt Issuances stands at -$5.4 million for Q3 2025, versus -$46.7 million for Q2 2025 and $2.5 billion for Q1 2025.